体外整体凝血检测揭示NXT007存在下血友病A联合止血药物可能剂量的启示
本研究采用凝血酶生成试验、凝块波形分析和旋转血栓弹力测量,在加入NXT007的血友病A血浆和全血样本中观察重组FVIII、重组FVIIa和活化凝血酶原复合物的体外效应。单剂NXT007≥10.0 μg/mL(血浆)即可达到非血友病凝血潜力;NXT007 15.0 μg/mL(全血)联合APCC 0.13 U/mL(相当于10.0 U/kg后即刻血药水平)的旋转血栓弹力参数与临床浓度艾米珠单抗联合APCC 0.63 U/mL(相当于推荐初始剂量50.0 U/kg后即刻水平)相当。
要点
- 单剂NXT007≥10.0 μg/mL(血浆)在体外达到非血友病凝血潜力。
- NXT007 0.1至50.0 μg/mL时,联用rFVIII、rFVIIa或APCC均增强多项凝血参数。
- NXT007 15.0 μg/mL联合APCC 0.13 U/mL的旋转血栓弹力参数与艾米珠单抗联合APCC 0.63 U/mL相当。
核心结论
- 体外联合加入凝血药物可在NXT007存在下提高凝血潜力。
- 当探索在血浆NXT007水平约30.0 μg/mL时联用APCC,10.0 U/kg的剂量或可作为初始剂量的粗略参考指标。
- 血浆NXT007≥10.0 μg/mL在体外显示非血友病凝血潜力。
研究设计与样本
- 体外研究,采用凝血酶生成试验、凝块波形分析和旋转血栓弹力测量,使用加入NXT007等的血友病A血浆和全血样本。
主要发现
- 单剂NXT007≥10.0 μg/mL(血浆)达到非血友病凝血潜力。
- 在NXT007 0.1至50.0 μg/mL水平下,联合加入rFVIII、rFVIIa和APCC各自增强多项参数。
- NXT007 15.0 μg/mL(全血)与APCC 0.13 U/mL(相当于10.0 U/kg给药后即刻血药水平)共存时,旋转血栓弹力参数与临床艾米珠单抗水平联合APCC 0.63 U/mL(相当于推荐初始剂量50.0 U/kg给药后即刻血药水平)时观察到的参数相当。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Concomitant administration of activated prothrombin complex concentrate (APCC) at doses >100 U/kg/d is associated with thrombotic risk under emicizumab prophylaxis. In vitro global assay data on the effects of concomitant coagulation factor agents in the presence of NXT007, an emicizumab-based engineered bispecific antibody under clinical development, may serve as a basis for addressing this potential risk. OBJECTIVES: This study aimed to investigate the in vitro effects of recombinant factor (rF)VIII, rFVIIa, and APCC during NXT007 treatment and estimate tolerable doses with reference to emicizumab. METHODS: Thrombin generation assays, clot waveform analysis, and rotational thromboelastometry were performed using hemophilia A plasma and blood samples spiked with NXT007 and others. RESULTS: A single dose of NXT007 at ≥10.0 μg/mL (plasma) achieved a nonhemophiliac coagulation potential. The concomitant addition of rFVIII, rFVIIa, and APCC each boosted various parameters following NXT007 levels at 0.1 to 50.0 μg/mL. In the copresence of NXT007 at 15.0 μg/mL (blood) and APCC at 0.13 U/mL, with the blood level immediately following the administration of 10.0 U/kg, the rotational thromboelastometry parameters were comparable with those observed with clinical emicizumab level and APCC at 0.63 U/mL, corresponding to the blood level immediately after administrating 50.0 U/kg (recommended initial dose). CONCLUSION: Concomitant addition of coagulation agents increased coagulation potentials in vitro in the presence of NXT007. A dose of 10.0 U/kg may serve as a rough indicator for the initial dose when exploring the concomitant use of APCC at plasma NXT007 levels of ∼30.0 μg/mL. Importantly, plasma NXT007 at ≥10.0 μg/mL demonstrated non-hemophiliac coagulation potentials in vitro.
引用
- Ogiwara K, Furukawa S, Inaba K, et al. Insights from in vitro global assays on possible doses of concomitant hemostatic agents in the presence of NXT007 in hemophilia A. J Thromb Haemost. 2025. PMID: 40199443. doi:10.1016/j.jtha.2025.03.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。